Tong Li1, Tatiana Khokhlova2, Ezekiel Maloney3, Yak-Nam Wang1, Samantha D'Andrea2, Frank Starr1, Navid Farr4, Kyle Morrison5, George Keilman5, Joo Ha Hwang6. 1. Center for Industrial and Medical Ultrasound, Applied Physics Laboratory, University of Washington, Seattle, Washington, USA. 2. Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington, USA; Applied Physics Laboratory, University of Washington, Seattle, Washington, USA. 3. Department of Radiology, University of Washington, Seattle, Washington, USA. 4. Department of Bioengineering, University of Washington, Seattle, Washington, USA. 5. Sonic Concepts, Bothell, Washington, USA. 6. Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: High-intensity focused US (HIFU) is becoming more widely used for noninvasive and minimally invasive ablation of benign and malignant tumors. Recent studies suggest that HIFU can also enhance targeted drug delivery and stimulate an antitumor immune response in many tumors. However, targeting pancreatic and liver tumors by using an extracorporeal source is challenging due to the lack of an adequate acoustic window. The development of an EUS-guided HIFU transducer has many potential benefits including improved targeting, decreased energy requirements, and decreased potential for injury to intervening structures. OBJECTIVE: To design, develop, and test an EUS-guided HIFU transducer for endoscopic applications. DESIGN: A preclinical, pilot characterization and feasibility study. SETTING: Academic research center. PATIENTS: Studies were performed in an in vivo porcine model. INTERVENTION: Thermal ablation of in vivo porcine pancreas and liver was performed with EUS-guided focused US through the gastric tract. RESULTS: The transducer successfully created lesions in gel phantoms and ex vivo bovine livers. In vivo studies demonstrated that targeting and creating lesions in the porcine pancreas and liver are feasible. LIMITATIONS: This was a preclinical, single-center feasibility study with a limited number of subjects. CONCLUSION: An EUS-guided HIFU transducer was successfully designed and developed with dimensions that are appropriate for endoscopic use. The feasibility of performing EUS-guided HIFU ablation in vivo was demonstrated in an in vivo porcine model. Further development of this technology will allow endoscopists to perform precise therapeutic ablation of periluminal lesions without breaching the wall of the gastric tract.
BACKGROUND: High-intensity focused US (HIFU) is becoming more widely used for noninvasive and minimally invasive ablation of benign and malignant tumors. Recent studies suggest that HIFU can also enhance targeted drug delivery and stimulate an antitumor immune response in many tumors. However, targeting pancreatic and liver tumors by using an extracorporeal source is challenging due to the lack of an adequate acoustic window. The development of an EUS-guided HIFU transducer has many potential benefits including improved targeting, decreased energy requirements, and decreased potential for injury to intervening structures. OBJECTIVE: To design, develop, and test an EUS-guided HIFU transducer for endoscopic applications. DESIGN: A preclinical, pilot characterization and feasibility study. SETTING: Academic research center. PATIENTS: Studies were performed in an in vivo porcine model. INTERVENTION: Thermal ablation of in vivo porcine pancreas and liver was performed with EUS-guided focused US through the gastric tract. RESULTS: The transducer successfully created lesions in gel phantoms and ex vivo bovine livers. In vivo studies demonstrated that targeting and creating lesions in the porcine pancreas and liver are feasible. LIMITATIONS: This was a preclinical, single-center feasibility study with a limited number of subjects. CONCLUSION: An EUS-guided HIFU transducer was successfully designed and developed with dimensions that are appropriate for endoscopic use. The feasibility of performing EUS-guided HIFU ablation in vivo was demonstrated in an in vivo porcine model. Further development of this technology will allow endoscopists to perform precise therapeutic ablation of periluminal lesions without breaching the wall of the gastric tract.
Authors: Tatiana D Khokhlova; Michael S Canney; Vera A Khokhlova; Oleg A Sapozhnikov; Lawrence A Crum; Michael R Bailey Journal: J Acoust Soc Am Date: 2011-11 Impact factor: 1.840
Authors: Franco Orsi; Lian Zhang; Paolo Arnone; Gianluigi Orgera; Guido Bonomo; Paolo Della Vigna; Lorenzo Monfardini; Kun Zhou; Wenzhi Chen; Zhibiao Wang; Umberto Veronesi Journal: AJR Am J Roentgenol Date: 2010-09 Impact factor: 3.959
Authors: M Pioche; C Lafon; E Constanciel; A Vignot; A Birer; R Gincul; V Lépilliez; F Prat; S Roman; J-Y Chapelon; J C Saurin; T Ponchon Journal: Endoscopy Date: 2012-09-25 Impact factor: 10.093
Authors: Matthew S Adams; Vasant A Salgaonkar; Juan Plata-Camargo; Peter D Jones; Aurea Pascal-Tenorio; Hsin-Yu Chen; Donna M Bouley; Graham Sommer; Kim Butts Pauly; Chris J Diederich Journal: Med Phys Date: 2016-07 Impact factor: 4.071
Authors: Xiaoyang Liu; Nicholas Ellens; Emery Williams; Everette C Burdette; Parag Karmarkar; Clifford R Weiss; Dara Kraitchman; Paul A Bottomley Journal: Magn Reson Med Date: 2019-08-11 Impact factor: 4.668
Authors: Linda S Lee; Dana K Andersen; Reiko Ashida; William R Brugge; Mimi I Canto; Kenneth J Chang; Suresh T Chari; John DeWitt; Joo Ha Hwang; Mouen A Khashab; Kang Kim; Michael J Levy; Kevin McGrath; Walter G Park; Aatur Singhi; Tyler Stevens; Christopher C Thompson; Mark D Topazian; Michael B Wallace; Sachin Wani; Irving Waxman; Dhiraj Yadav; Vikesh K Singh Journal: Pancreas Date: 2017 Nov/Dec Impact factor: 3.327
Authors: Matthew S Adams; Vasant A Salgaonkar; Serena J Scott; Graham Sommer; Chris J Diederich Journal: Med Phys Date: 2017-08-08 Impact factor: 4.071
Authors: Matthew S Adams; Serena J Scott; Vasant A Salgaonkar; Graham Sommer; Chris J Diederich Journal: Int J Hyperthermia Date: 2016-01-21 Impact factor: 3.914